WeTrials
Recruiting

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

What is this study?

This study tests an experimental drug called JAB-2485 in adults with advanced solid tumors, including certain types of breast and lung cancers. The goal is to see if this medicine is safe and helps stop cancer cells from dividing by blocking a specific protein.

Who can participate?

You may be eligible if you have advanced cancer that has stopped responding to standard treatments and you are able to carry out normal daily activities. You will also need to provide a stored tumor sample and meet specific heart health and infection-free requirements.

What will happen?

Participants will receive the study drug, JAB-2485, while doctors closely monitor their safety, overall health, and how the medicine affects their tumors using regular imaging scans. Your medical team will guide you through every step and check in on you often.

Where and when?

The study is currently active and recruiting participants at medical centers in Detroit, Michigan; St. Louis, Missouri; and Dallas, Texas. Speak with your doctor to see if one of these locations is a good fit for you.

Key Points
  • 1Evaluating the safety of a new drug called JAB-2485 for advanced solid tumors
  • 2Open to adults whose previous cancer treatments have stopped working
  • 3Currently recruiting patients at multiple locations in the United States

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBCARID1A Gene MutationSmall Cell Lung Cancer, SCLC

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.